Personalis sees FY24 revenue $83M-$84M, consensus $79.85M

Revenue from pharma tests, enterprise sales, and all other customers in the range of $76 to $77 million, an increase from prior guidance of $71 to $73 million; Revenue from population sequencing of approximately $7 million, a decrease from prior guidance of $8 million; Net loss of approximately $85 million, which includes approximately $18 million of net, non-cash expense from the warrants issued to Tempus; Cash usage in the range of $53 to $55 million, a decrease from prior guidance of $60 million.